-
1
-
-
43449127502
-
Prostate cancer
-
Damber, J. E.; Aus, G. Prostate cancer Lancet 2008, 371, 1710-1721
-
(2008)
Lancet
, vol.371
, pp. 1710-1721
-
-
Damber, J.E.1
Aus, G.2
-
2
-
-
40149099162
-
Chemotherapy in hormone-refractory prostate cancer
-
de Wit, R. Chemotherapy in hormone-refractory prostate cancer BJU Int. 2008, 101 (Suppl. 2) 11-15
-
(2008)
BJU Int.
, vol.101
, Issue.SUPPL. 2
, pp. 11-15
-
-
De Wit, R.1
-
3
-
-
34249690674
-
Modulating paclitaxel bioavailability for targeting prostate cancer
-
Kumar, S. K.; Williams, S. A.; Isaacs, J. T.; Denmeade, S. R.; Khan, S. R. Modulating paclitaxel bioavailability for targeting prostate cancer Bioorg. Med. Chem. 2007, 15, 4973-4984
-
(2007)
Bioorg. Med. Chem.
, vol.15
, pp. 4973-4984
-
-
Kumar, S.K.1
Williams, S.A.2
Isaacs, J.T.3
Denmeade, S.R.4
Khan, S.R.5
-
4
-
-
39349084237
-
Prodrug strategies in anticancer chemotherapy
-
Kratz, F.; Muller, I. A.; Ryppa, C.; Warnecke, A. Prodrug strategies in anticancer chemotherapy ChemMedChem 2008, 3, 20-53
-
(2008)
ChemMedChem
, vol.3
, pp. 20-53
-
-
Kratz, F.1
Muller, I.A.2
Ryppa, C.3
Warnecke, A.4
-
5
-
-
56949084877
-
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
-
Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 2008, 132, 171-183
-
(2008)
J. Controlled Release
, vol.132
, pp. 171-183
-
-
Kratz, F.1
-
6
-
-
0034000453
-
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
-
Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review J. Controlled Release 2000, 65, 271-284
-
(2000)
J. Controlled Release
, vol.65
, pp. 271-284
-
-
Maeda, H.1
Wu, J.2
Sawa, T.3
Matsumura, Y.4
Hori, K.5
-
7
-
-
0037028050
-
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound
-
Kratz, F.; Warnecke, A.; Scheuermann, K.; Stockmar, C.; Schwab, J.; Lazar, P.; Drückes, P.; Esser, N.; Drevs, J.; Rognan, D.; Bissantz, C.; Hinderling, C.; Folkers, G.; Fichtner, I.; Unger, C. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound J. Med. Chem. 2002, 45, 5523-5533
-
(2002)
J. Med. Chem.
, vol.45
, pp. 5523-5533
-
-
Kratz, F.1
Warnecke, A.2
Scheuermann, K.3
Stockmar, C.4
Schwab, J.5
Lazar, P.6
Drückes, P.7
Esser, N.8
Drevs, J.9
Rognan, D.10
Bissantz, C.11
Hinderling, C.12
Folkers, G.13
Fichtner, I.14
Unger, C.15
-
8
-
-
0042173127
-
A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2
-
Mansour, A. M.; Drevs, J.; Esser, N.; Hamada, F. M.; Badary, O. A.; Unger, C.; Fichtner, I.; Kratz, F. A new approach for the treatment of malignant melanoma: Enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2 Cancer Res. 2003, 63, 4062-4066
-
(2003)
Cancer Res.
, vol.63
, pp. 4062-4066
-
-
Mansour, A.M.1
Drevs, J.2
Esser, N.3
Hamada, F.M.4
Badary, O.A.5
Unger, C.6
Fichtner, I.7
Kratz, F.8
-
9
-
-
34249980937
-
DOXO-EMCH (INNO-206): The first albumin-binding prodrug of doxorubicin to enter clinical trials
-
Kratz, F. DOXO-EMCH (INNO-206): The first albumin-binding prodrug of doxorubicin to enter clinical trials Expert Opin. Invest. Drugs 2007, 16, 855-866
-
(2007)
Expert Opin. Invest. Drugs
, vol.16
, pp. 855-866
-
-
Kratz, F.1
-
10
-
-
34347354414
-
Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy
-
Schmid, B.; Chung, D. E.; Warnecke, A.; Fichtner, I.; Kratz, F. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy Bioconjugate Chem. 2007, 18, 702-716
-
(2007)
Bioconjugate Chem.
, vol.18
, pp. 702-716
-
-
Schmid, B.1
Chung, D.E.2
Warnecke, A.3
Fichtner, I.4
Kratz, F.5
-
11
-
-
33747339731
-
Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA)
-
Chung, D. E.; Kratz, F. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA) Bioorg. Med. Chem. Lett. 2006, 16, 5157-5163
-
(2006)
Bioorg. Med. Chem. Lett.
, vol.16
, pp. 5157-5163
-
-
Chung, D.E.1
Kratz, F.2
-
12
-
-
27644436770
-
Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen (PSA)
-
Kratz, F.; Mansour, A.; Soltau, J.; Warnecke, A.; Fichtner, I.; Unger, C.; Drevs, J. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen (PSA) Arch. Pharm. 2005, 338, 462-472
-
(2005)
Arch. Pharm.
, vol.338
, pp. 462-472
-
-
Kratz, F.1
Mansour, A.2
Soltau, J.3
Warnecke, A.4
Fichtner, I.5
Unger, C.6
Drevs, J.7
-
13
-
-
38749154289
-
Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP)
-
Graeser, R.; Chung, D. E.; Esser, N.; Moor, S.; Schachtele, C.; Unger, C.; Kratz, F. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP) Int. J. Cancer 2008, 122, 1145-1154
-
(2008)
Int. J. Cancer
, vol.122
, pp. 1145-1154
-
-
Graeser, R.1
Chung, D.E.2
Esser, N.3
Moor, S.4
Schachtele, C.5
Unger, C.6
Kratz, F.7
-
14
-
-
34548067350
-
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B
-
Warnecke, A.; Fichtner, I.; Sass, G.; Kratz, F. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B Arch. Pharm. (Weinheim) 2007, 340, 389-395
-
(2007)
Arch. Pharm. (Weinheim)
, vol.340
, pp. 389-395
-
-
Warnecke, A.1
Fichtner, I.2
Sass, G.3
Kratz, F.4
-
15
-
-
0023622310
-
The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein
-
Akiyama, K.; Nakamura, T.; Iwanaga, S.; Hara, M. The chymotrypsin-like activity of human prostate-specific antigen, gamma-seminoprotein FEBS Lett. 1987, 225, 168-172
-
(1987)
FEBS Lett.
, vol.225
, pp. 168-172
-
-
Akiyama, K.1
Nakamura, T.2
Iwanaga, S.3
Hara, M.4
-
16
-
-
0028918466
-
New diagnostic applications and physiological functions of prostate specific antigen
-
Diamandis, E. P. New diagnostic applications and physiological functions of prostate specific antigen Scand. J. Clin. Lab. Invest. Suppl. 1995, 221, 105-112
-
(1995)
Scand. J. Clin. Lab. Invest. Suppl.
, vol.221
, pp. 105-112
-
-
Diamandis, E.P.1
-
17
-
-
0035876331
-
Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models
-
Denmeade, S. R.; Sokoll, L. J.; Chan, D. W.; Khan, S. R.; Isaacs, J. T. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models Prostate 2001, 48, 1-6
-
(2001)
Prostate
, vol.48
, pp. 1-6
-
-
Denmeade, S.R.1
Sokoll, L.J.2
Chan, D.W.3
Khan, S.R.4
Isaacs, J.T.5
-
18
-
-
0030991964
-
Free/total prostate-specific antigen ratio - Hope and controversies
-
Ravery, V.; Boccon-Gibod, L. Free/total prostate-specific antigen ratio - Hope and controversies Eur. Urol. 1997, 31, 385-388
-
(1997)
Eur. Urol.
, vol.31
, pp. 385-388
-
-
Ravery, V.1
Boccon-Gibod, L.2
-
19
-
-
0031813782
-
Enzymatic activation of prodrugs by prostate-specific antigen: Targeted therapy for metastatic prostate cancer
-
Denmeade, S. R.; Isaacs, J. T. Enzymatic activation of prodrugs by prostate-specific antigen: Targeted therapy for metastatic prostate cancer Cancer J. Sci. Am. 1998, 4 (Suppl. 1) S15-S21
-
(1998)
Cancer J. Sci. Am.
, vol.4
, Issue.SUPPL. 1
-
-
Denmeade, S.R.1
Isaacs, J.T.2
-
20
-
-
0033678680
-
A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo
-
DeFeo-Jones, D.; Garsky, V. M.; Wong, B. K.; Feng, D. M.; Bolyar, T.; Haskell, K.; Kiefer, D. M.; Leander, K.; McAvoy, E.; Lumma, P.; Wai, J.; Senderak, E. T.; Motzel, S. L.; Keenan, K.; Van Zwieten, M.; Lin, J. H.; Freidinger, R.; Huff, J.; Oliff, A.; Jones, R. E. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo Nat. Med. 2000, 6, 1248-1252
-
(2000)
Nat. Med.
, vol.6
, pp. 1248-1252
-
-
Defeo-Jones, D.1
Garsky, V.M.2
Wong, B.K.3
Feng, D.M.4
Bolyar, T.5
Haskell, K.6
Kiefer, D.M.7
Leander, K.8
McAvoy, E.9
Lumma, P.10
Wai, J.11
Senderak, E.T.12
Motzel, S.L.13
Keenan, K.14
Van Zwieten, M.15
Lin, J.H.16
Freidinger, R.17
Huff, J.18
Oliff, A.19
Jones, R.E.20
more..
-
21
-
-
0033843895
-
In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts
-
Khan, S. R.; Denmeade, S. R. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts Prostate 2000, 45, 80-83
-
(2000)
Prostate
, vol.45
, pp. 80-83
-
-
Khan, S.R.1
Denmeade, S.R.2
-
22
-
-
0019453510
-
A novel connector linkage applicable in prodrug design
-
Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A. A novel connector linkage applicable in prodrug design J. Med. Chem. 1981, 24, 479-480
-
(1981)
J. Med. Chem.
, vol.24
, pp. 479-480
-
-
Carl, P.L.1
Chakravarty, P.K.2
Katzenellenbogen, J.A.3
-
23
-
-
0032402354
-
Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin
-
Dubowchik, G. M.; Firestone, R. A. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin Bioorg. Med. Chem. Lett. 1998, 8, 3341-3346
-
(1998)
Bioorg. Med. Chem. Lett.
, vol.8
, pp. 3341-3346
-
-
Dubowchik, G.M.1
Firestone, R.A.2
-
24
-
-
0033814795
-
Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by Zn(2+), a tight-binding inhibitor
-
Malm, J.; Hellman, J.; Hogg, P.; Lilja, H. Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by Zn(2+), a tight-binding inhibitor Prostate 2000, 45, 132-139
-
(2000)
Prostate
, vol.45
, pp. 132-139
-
-
Malm, J.1
Hellman, J.2
Hogg, P.3
Lilja, H.4
-
25
-
-
77956168233
-
A novel albumin-binding prodrug of doxorubicin with improved efficacy against prostate cancer metastases
-
submitted for publication
-
Elsadek, B.; Graeser, R.; Esser, N.; Schäfer-Obodozie, C.; Tsurumi, C. A novel albumin-binding prodrug of doxorubicin with improved efficacy against prostate cancer metastases. Int. J. Cancer 2010, submitted for publication.
-
(2010)
Int. J. Cancer
-
-
Elsadek, B.1
Graeser, R.2
Esser, N.3
Schäfer-Obodozie, C.4
Tsurumi, C.5
|